Compare NPWR & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPWR | SOPH |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.1M | 330.4M |
| IPO Year | N/A | 2021 |
| Metric | NPWR | SOPH |
|---|---|---|
| Price | $2.18 | $4.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.50 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 897.9K | 75.4K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $73,297,000.00 |
| Revenue This Year | N/A | $18.32 |
| Revenue Next Year | N/A | $15.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.86 | 13.66 |
| 52 Week Low | $1.48 | $2.58 |
| 52 Week High | $11.83 | $5.30 |
| Indicator | NPWR | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 32.70 | 52.12 |
| Support Level | $2.12 | $4.50 |
| Resistance Level | $2.28 | $4.84 |
| Average True Range (ATR) | 0.16 | 0.22 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 9.98 | 48.00 |
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.